ஜூலியன் மியாரா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜூலியன் மியாரா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜூலியன் மியாரா Today - Breaking & Trending Today

Onxeo S.A.: Onxeo Reports Its 2021 Half-Yearly Financial Results and Provides an Update on Its Activities

Onxeo S.A.: Onxeo Reports Its 2021 Half-Yearly Financial Results and Provides an Update on Its Activities
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , France General , Walter Thomas Hofstaetter , Nicolas Merigeau , Julien Miara , Jean Pierre Bizzari , Acrotech Biopharma , Judith Greciet , Emmanuel Huynh , Shefali Agarwal , Onxeo Sa Euronext , Valerie Leroy , Gustave Roussy , Institut Curie , American Association For Cancer Research , Scientific Advisory Committee , Company Group , Euronext Growth Paris , Nasdaq First North , Chief Executive Officer , State Guaranteed , General Meeting , European Fight Kids Cancer , European Innovative Therapies , Oncology Cancer Case Reports , American Association ,

Onxeo S.A.: Onxeo: Report on the Combined General Meeting of June 10, 2021

Onxeo S.A.: Onxeo: Report on the Combined General Meeting of June 10, 2021
Shefali Agarwal, MD, a clinical development expert in oncology, is appointed Director of Onxeo
Regulatory News:
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, announced that the Combined General Meeting held today in camera adopted all the resolutions presented, in accordance with the recommendations of the Board of Directors.
The shareholders of the Company also renewed for three years the mandate of Mr. Thomas Hofstaetter, which expired at the end of this General Meeting and ratified the appointment of Mr. Julien Miara, representing Invus, to replace Mr. Jean-Pierre Kinet until the expiry of his mandate, at the end of the Meeting called to approve the accounts for the year ended December 31, 2021. ....

United States , France General , Jean Pierre Kinet , Nicolas Merigeau , Julien Miara , Emmanuel Huynh , Shefali Agarwal , Valerie Leroy , Onxeo Sa Euronext , Gustave Roussy , Thomas Hofstaetter , Institut Curie , Company Group , Clinical Development , Euronext Growth Paris , Nasdaq First North , Combined General Meeting , General Meeting , Executive Vice President , Chief Medical , Clinical Development Officer , General Meetings , Euronext Paris , Inhibitor Administered Intravenously , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் ,

Onxeo's Combined General Meeting on June 10, 2021 in Camera: Availability of Preparatory Documents and Live Webcast Login Information

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), ("Onxeo", "the Company" or "the Group"), a clinical-stage biotechnology company specializing in the development ....

France General , Nicolas Fellmann , Nicolas Merigeau , Julien Miara , Emmanuel Huynh , Valerie Leroy , Onxeo Sa Euronext , Gustave Roussy , Institut Curie , Nicolas Trebouta , Company Group , Regulatory News , Euronext Paris , Combined General Meeting , General Meeting , General Meetings , Mrs Dani , Chief Financial Officer , Invus Public Equities , Investor Relations , French Commercial , Euronext Growth Paris , Nasdaq First North Copenhagen , Inhibitor Administered Intravenously , பிரான்ஸ் ஜநரல் , ஜூலியன் மியாரா ,

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
Regulatory News:
https://us02web.zoom.us/webinar/register/WN T6v8Hc8TRU67rKXPrz2nXw
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) (Paris:ALONX) (NASDAQ OMX:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today reported its consolidated financial results for the fiscal e ....

United States , France General , Jean Pierre Kinet , Nicolas Merigeau , Julien Miara , Acrotech Biopharma , Vectans Pharma , Judith Greciet , Emmanuel Huynh , Onxeo Sa Euronext , Valerie Leroy , Gustave Roussy , Institut Curie , European Named Patient Program , Curie Institute , Trademark Office , American Association For Cancer Research , Holdings Corporation , Company Group , Board Of Directors The Company , Euronext Growth Paris , Nasdaq First North Copenhagen , Chief Executive Officer , Invus Public Equities , State Guaranteed Loans , American Association ,